Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011053 (
deafness
)
10,271
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The sixteenth gene to cause autosomal dominant nonsyndromic hearing loss (ADNSHL),
DFNA16
, maps to chromosome 2q23-24.3 and is tightly linked to markers in the D2S2380-D2S335 interval.
DFNA16
is unique in that it results in the only form of ADNSHL in which the phenotype includes rapidly progressing and fluctuating hearing loss that appears to respond to steroid therapy. This observation suggests that it may be possible to stabilize hearing through medical intervention, once the biophysiology of
deafness
due to
DFNA16
is clarified. Especially intriguing is the localization of several voltage-gated sodium-channel genes to the
DFNA16
interval. These cationic channels are excellent positional and functional
DFNA16
candidate genes.
...
PMID:A gene for fluctuating, progressive autosomal dominant nonsyndromic hearing loss, DFNA16, maps to chromosome 2q23-24.3. 1036 26
Non-syndromic sensorineural
deafness
is an extremely genetically heterogeneous condition. We have used autozygosity mapping in a large consanguineous United Arab Emirate family to identify a novel locus for autosomal recessive non-syndromic sensorineural
deafness
, DFNB27, on chromosome 2q23-q31, with a maximum two-point lod score of 5.18 at theta = 0 for marker D2S2257. The DFNB27 locus extends over a 17 cM region between D2S2157 and D2S2273, and may overlap the
DFNA16
locus for dominantly inherited, fluctuating, progressive non-syndromal hearing loss. However, genotype data suggests that the locus is likely to be refined to between D2S326 and D2S2273 and thus distinct from the
DFNA16
locus.
...
PMID:A new locus for autosomal recessive non-syndromal sensorineural hearing impairment (DFNB27) on chromosome 2q23-q31. 1117 89
DFNA16
is a form of autosomal dominant non-syndromic hearing loss (ADNSHL) characterized by fluctuating progressive hearing impairment. Earlier, we mapped the
deafness
-causing gene to chromosome 2q23-24.3. In this paper, we describe fine mapping results using additional markers tightly linked to the
DFNA16
candidate region. Critical recombinants at markers D2S354 and D2S124 define a 3.5-cM interval that contains the
DFNA16
gene. Positional candidate genes include two members of the voltage-gated sodium channel family, the type 2 alpha subunit (SCN2A) and the type 3 alpha subunit (SCN3A). After showing that SCN2A is expressed in human fetal cochlea, we determined its genomic structure to facilitate mutation screening in our
DFNA16
kindred. We also determined the genomic structure of SCN3A. These two genes are oriented head-to-head, with their 5' ends separated by approximately 40 kb; their homology is 82% at the nucleotide level, and 85% for identities and 90% for positives at the amino acid level. They share similar genomic structures and have alternative splice isoforms that are developmentally regulated and highly conserved between species. Although no
DFNA16
-causing mutations were found in either gene, haplotype analysis with polymorphic markers in SCN2A introns further narrowed the candidate gene interval to the region flanked by D2S354 and STS SHGC-82894.
...
PMID:Genomic structures of SCN2A and SCN3A - candidate genes for deafness at the DFNA16 locus. 1124 85